Drug Trial Radar · NCT06277492
A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Feb 19, 2024
Primary completion
Jul 11, 2025
Study completion Nov 27, 2025
Sponsor
- Lead sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.Industry
- Sponsor type
- Industry
- Collaborators
- Sulfateq B.V.
- First posted
- Feb 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this randomized, double-blind, placebo-controlled, single-center study is to evaluate the safety, tolerability, pharmacokinetics of single and multiple oral doses of SUL-238 in healthy subjects (aged ≥40 years).
Conditions
- Healthy Subjects
Interventions
Single ascending doses SUL-238Drug
PART 1: SUL-238 single ascending doses
Single dose PlaceboDrug
PART 1: Placebo single dose
Single dose SUL-238Drug
PART 2: SUL-238 single dose for pharmacokinetics
Multiple ascending doses SUL-238Drug
PART 3: SUL-238 multiple ascending doses
Multiple doses PlaceboDrug
PART 3: Placebo multiple doses
2000 mg SUL-238 single dose for pharmacokinetics (food effect)Drug
PART 2B: 2000 mg single dose of SUL-238
Single dose placebo (food effect)Drug
PART 2B: Placebo single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events as Measured by NCI-CTCAE criteriaTime frame: Up to day 29
- Incidence of Treatment-Emergent Adverse Events as Measured by Clinical Laboratory Measurements According to Established Clinical Normal RangesTime frame: Up to day 29
- Incidence of Treatment-Emergent Adverse Events as Measured by ECGTime frame: Up to day 29
- Incidence of Treatment-Emergent Adverse Events as Measured by physical examination and vital signsTime frame: Up to day 29
- Incidence of Treatment-Emergent Adverse Events as Measured by central nervous system (CNS) and autonomic nervous system (ANS) examination.Time frame: Up to day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Erciyes University IKUM Center
Kayseri, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.